November 3rd, 2021 | 10:16 CET
Valneva, Cardiol Therapeutics, BioNTech - Is the vaccination subscription coming?
The numbers of people infected with Corona have been rising significantly again for weeks. While only about 67% of Germans are fully vaccinated, the pace is slowing noticeably. Meanwhile, the third dose, the so-called "booster" vaccination, has already been started. The Standing Commission on Vaccination (STIKO) has recommended this booster for people aged 70 and over. A decision on whether booster vaccinations should be offered to everyone is likely to be made soon. For vaccine manufacturers, this means recurring revenues.
time to read: 2 minutes
|
Author:
Stefan Feulner
ISIN:
VALNEVA SE EO -_15 | FR0004056851 , CARDIOL THERAPEUTICS | CA14161Y2006 , BIONTECH SE SPON. ADRS 1 | US09075V1026
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Valneva - Waiting for the substance
The discussions about the various types of vaccines are endless. Besides the mRNA vaccines from BioNTech and Moderna, vector vaccines like AstraZeneca have been administered. Vaccination skeptics have criticized the mRNA vaccine in particular. Because of the accusation that it affects our genetic material, they have so far stayed away from protection against the coronavirus and are waiting for the first inactivated vaccine, which the Austrian-French Company Valneva wants to bring to approval.
Inactivated vaccines contain killed pathogens, i.e. pathogens that cannot reproduce or only their components. These are recognized by the body as foreign and stimulate the body's defense system to produce antibodies without the respective disease breaking out.
With a successfully completed capital increase and gross proceeds of approximately EUR 88.00 million, Valneva's vaccine projects are to be accelerated. The project pipeline is bulging. In addition to the COVID-19 vaccine VLA2001, additional money must be invested in the Chikungunya vaccine candidate VLA1553 and VLA15 for protection against Lyme disease. Studies to date show the potential of the inactivated vaccine. VLA2001 has achieved a higher level of antibodies with fewer side effects compared with the AstraZeneca vaccine in about 4,000 subjects over the age of 18, the Company said.
Cardiol Therapeutics - Blockbuster for the heart
An infection with the SARS-CoV-2 coronavirus can also attack the heart, and in some cases, possibly lead to myocarditis. Recently, it has also been discussed that inflammation of the heart muscle, and in some cases also of the pericardium, occurs in a few patients following the Covid-19 vaccination, especially with a so-called mRNA vaccine.
Cardiol Therapeutics, a Canadian biotechnology company listed on Nasdaq, focuses on producing pharmaceutical cannabidiol (CBD) products and the development of innovative therapies for heart disease, including acute myocarditis and other causes of heart failure. Cardiol's lead product, CardiolRX, a highly purified and concentrated oral cannabidiol formulation, is the focus of this effort and is currently being evaluated in a Phase II/III outcomes study.
The Company received positive news from Health Canada, which granted approval to continue work on the multicenter, double-blind, randomized, placebo-controlled Phase II study designed to evaluate the safety and tolerability of CardiolRx and its effects on myocardial regeneration in patients with acute myocarditis. The study is expected to enroll 100 patients in clinical centers in the United States, Canada and Europe.
Cardiovascular disease is the leading cause of death in the Western world, independent of SARS-CoV-2. Cardiol Therapeutics has successfully progressed through the phases to date and continues to have tremendous potential in a multi-billion dollar market.
BioNTech - In the wake of the partner
The share price of the Mainz-based biotech Company benefited from the third quarter figures of its partner Pfizer, which exploded due to the joint preparation Comirnaty. Sales increased by 130% to USD 24.1 billion. The main sales driver was the jointly developed compound.
If Comirnaty is excluded from the figures, revenue growth of only 7% to USD 11.1 billion remains. BioNTech itself will publish its 9-month figures on November 9.
The share price reaction shows investors' expectations with a 3% gain to EUR 282.20. Above the level of around EUR 285.00, there should be a renewed attack on the October high at EUR 304.00.
Infection figures are rising rapidly again, but the pace of vaccination is slowing. To achieve better protection against the virus, "booster" vaccinations for all are currently being discussed, which will, of course, give the already approved vaccines such as Comirnaty a further boost in sales. BioNTech is promising, while we should wait and see with Valneva. Cardiol Therapeutics also has enormous potential with its preparation against heart disease.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
